Literature DB >> 3226510

Treatment of intact familial intracranial aneurysms: a decision-analytical approach.

H W ter Berg1, D W Dippel, J D Habbema, J B Bijlsma, J van Gijn, C A Tulleken, J Willemse.   

Abstract

Clinical decision analysis is applied to the treatment decisions for four patients with unruptured familial aneurysms. The surgical treatment was uneventful in all patients except one with mild mixed aphasia and facial weakness postoperatively; these deficits disappeared in less than 2 years. In the decision analysis, discounted Quality Adjusted Life Years are used as an outcome measure. Probability estimates are extracted from the literature when available. It is concluded that the decision to treat the aneurysm neurosurgically in three of the four patients was correct. In two of these three patients, the decision cannot be altered by plausible changes in estimated data. For the third patient, only the combination of a low probability of rupture, a high surgical mortality and morbidity, and high discount favors conservative treatment. In the fourth patient, a toss-up situation exists. More knowledge of the probability of rupture, the probability of the development of other aneurysms, and the results of operation on intact intracranial aneurysms would have made the analysis more accurate. Clinical research should address these issues.

Entities:  

Mesh:

Year:  1988        PMID: 3226510     DOI: 10.1227/00006123-198809000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  2 in total

1.  Risk analysis of treatment of unruptured aneurysms.

Authors:  P Mitchell; J Jakubowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

2.  Unruptured intracranial arteriovenous malformations with hereditary haemorrhagic telangiectasia. Neurosurgical treatment or not?

Authors:  J W ter Berg; D W Dippel; J D Habbema; C J Westermann; C A Tulleken; J Willemse
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.